NeoGenomics (NEO) News Today

Edgestream Partners L.P. bought a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 120,456 shares of the medical research company's stock, val

Susquehanna Fundamental Investments LLC purchased a new stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 43,288 shares of the medical research

Susquehanna Portfolio Strategies LLC lowered its position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 56.5% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 73,234 shares of the medical research company's stock after selling 95,061

Jennison Associates LLC lifted its position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 77.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,051,627 shares of the medical research company

NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating

Vanguard Group Inc. decreased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 1.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 14,169,665 shares of the medical research company's stock after selling 146,536 shares du

NeoGenomics (NASDAQ:NEO) Trading 4.8% Higher

NeoGenomics (NASDAQ:NEO) Trading Up 8.8%

First Light Asset Management LLC increased its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 29.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 3,926,756 shares of the medical research company's stock after purchasing an additional 8

Norges Bank purchased a new stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 896,885 shares of the medical research company's stoc

BNP Paribas Financial Markets cut its position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 52.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 101,361 shares of the medical research company's stock after selling 113,442 sh

Brown Advisory Inc. raised its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 16.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,643,599 shares of the medical research company's stock after buying an add

Lisanti Capital Growth LLC acquired a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 212,935 shares of the medical research company's stock, valued at approximately $3,445,

BTIG Research dropped their price target on shares of NeoGenomics from $23.00 to $21.00 and set a "buy" rating on the stock in a research report on Thursday.

TD Cowen decreased their price target on shares of NeoGenomics from $21.00 to $20.00 and set a "buy" rating on the stock in a research note on Wednesday.

Benchmark reiterated a "buy" rating and issued a $18.00 target price on shares of NeoGenomics in a report on Wednesday.

Craig Hallum assumed coverage on NeoGenomics in a report on Wednesday. They set a "buy" rating and a $26.00 price target for the company.

NeoGenomics (NASDAQ:NEO) Trading Down 7.7% After Analyst Downgrade

NeoGenomics (NASDAQ:NEO) updated its FY 2024 earnings guidance. The company provided EPS guidance of 0.000-0.040 for the period, compared to the consensus estimate of -0.010. The company also issued revenue guidance of $650.0 millionillion-$660.0 millionillion, compared to the consensus estimate of $654.6 millionillion.

NeoGenomics (NASDAQ:NEO) Trading Up 7.1%

Federated Hermes Inc. reduced its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 51.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 149,441 shares of the medical research company'

Jennison Associates LLC lifted its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 17.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 591,556 shares of the medical research company's stock after buying an addi

Semanteon Capital Management LP bought a new position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 69,986 shares of the medical research company's stock, valued at approximate

NeoGenomics (NASDAQ:NEO) Shares Up 7.4%